SBIOvsLFSCETF Comparison
VS
ALPS Medical Breakthroughs ETF (SBIO) belongs to the Tomorrow's Treatments segment. F/m Emerald Life Sciences Innovation ETF (LFSC) is part of the Life Sciences segment. SBIO's top 3 sector exposures are Healthcare and Non-Corporate. In contrast, LFSC's top sector exposures are Healthcare and Sovereign. SBIO is less expensive with a Total Expense Ratio (TER) of 0.5%, versus 0.79% for LFSC. SBIO is up 24.68% year-to-date (YTD) with +$41M in YTD flows. LFSC performs worse with 24.02% YTD performance, and +$8M in YTD flows. Run a side-by-side ETF comparison of SBIO and LFSC below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
SBIO vs LFSC performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/28/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | SBIO LFSC | -0.90%-0.18% | +19.27%+22.84% | +24.68%+24.02% | +92.66%+86.38% | +109.07%n/a | +44.84%n/a |
| Flows | SBIO LFSC | +$17M+$2M | +$23M+$3M | +$41M+$8M | +$51M+$17M | +$20M- | -$24M- |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | SBIO LFSC | +35.26%+25.87% | +30.57%+26.87% | +30.92%n/a | +33.91%n/a |
| Max drawdown | SBIO LFSC | -10.73%-6.53% | -12.63%-16.25% | -42.12%n/a | -52.50%n/a |
| Max drawdown duration | SBIO LFSC | 43d20d | 60d168d | 331dn/a | 1479dn/a |
Trading data
SBIO | LFSC | |
Last sale 7/29/2026 at 1:30 PM | $63.14 | $44.93 |
| Previous close 07/28/2026 | $63.52 | $45.40 |
| Consolidated volume 07/28/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
LFSC
is actively managed and doesn’t replicate an indexSBIO | LFSC | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/29/2026 at 1:30 PM
Live
Closed
SBIO | LFSC | |
|---|---|---|
| Last price | $63.14 | $44.93 |
| 1D performance | -0.60% | -1.02% |
| AuM | $202.41 M | $124.27 M |
| E/R | 0.5% | 0.79% |
Characteristics
SBIO | LFSC | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | ALPS | Emerald Group |
| Benchmark | S-Network Medical Breakthroughs Index | - |
| N° of holdings | 103 | 40 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 30, 2014 | October 31, 2024 |
| ESG | No | No |
Advertisement
Exposure
Countries
SBIO
USA
88.02%
Other
11.98%
LFSC
USA
90.9%
United Kingdom
7.04%
Other
2.06%
Sectors
SBIO
Healthcare
99.06%
Other
0.94%
LFSC
Healthcare
98.03%
Other
1.97%
Advertisement
Diversification
SBIO
Total weight of top 15 holdings out of 15
40.08%
LFSC
Total weight of top 15 holdings out of 15
73.24%
Top 15 holdings
Data as of June 30, 2026
SBIO
Apogee Therapeutics, Inc.
4.36%
CG Oncology, Inc.
3.33%
Xenon Pharmaceuticals, Inc.
3.09%
Oruka Therapeutics, Inc.
3.05%
Dianthus Therapeutics, Inc.
2.83%
Travere Therapeutics, Inc.
2.80%
Definium Therapeutics, Inc.
2.73%
Veradermics, Inc.
2.72%
Edgewise Therapeutics, Inc.
2.32%
ACADIA Pharmaceuticals, Inc.
2.30%
Denali Therapeutics, Inc.
2.17%
Relay Therapeutics, Inc.
2.17%
NewAmsterdam Pharma Co. NV
2.10%
Crinetics Pharmaceuticals, Inc.
2.09%
Structure Therapeutics, Inc.
2.02%
LFSC
Travere Therapeutics, Inc.
8.37%
Cogent Biosciences, Inc.
7.18%
LivaNova Plc
7.04%
Spyre Therapeutics, Inc.
6.71%
Guardant Health, Inc.
5.56%
Corcept Therapeutics, Inc.
5.27%
Mirum Pharmaceuticals, Inc.
5.25%
BillionToOne, Inc.
4.25%
Cytokinetics, Inc.
4.13%
Veradermics, Inc.
3.76%
United Therapeutics Corp.
3.55%
Trevi Therapeutics, Inc.
3.50%
Savara, Inc.
3.20%
Dianthus Therapeutics, Inc.
2.77%
Nektar Therapeutics
2.70%
Frequently asked questions about SBIO and LFSC
How have the SBIO and LFSC ETFs performed in 2026?
As of July 28, 2026, SBIO is up 24.68% year-to-date (YTD), while LFSC has returned 24.02%. That puts SBIO better performer ahead so far this year.
Which ETF is attracting more investor money: SBIO or LFSC?
Year-to-date, the SBIO ETF saw +$41M in flows, compared to +$8M for LFSC.
Which ETF is more volatile: SBIO or LFSC?
Over the past year, SBIO had a volatility of 30.57%, while LFSC experienced 26.87%.
Which ETF is bigger: SBIO or LFSC?
As of July 28, 2026, SBIO holds $202.41 M in assets under management (AUM), while LFSC manages $124.27 M.
What sectors do the SBIO and LFSC ETFs invest in?
SBIO leans toward sectors like Healthcare. Meanwhile, LFSC focuses on Healthcare.
What are the top holdings of the SBIO ETF and LFSC ETF?
SBIO top holdings include Apogee Therapeutics, Inc., CG Oncology, Inc. and Xenon Pharmaceuticals, Inc.. LFSC holds in its top three: Travere Therapeutics, Inc., Cogent Biosciences, Inc. and LivaNova Plc.
Which ETF is more diversified: SBIO or LFSC?
SBIO holds 104 securities with 40.08% of its assets in the top 15. LFSC has 40 securities and a top 15 weight of 73.24%.
Advertisement
Latest news about SBIO & LFSC
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Advertisement
Advertisement
